192 related articles for article (PubMed ID: 20297846)
1. Discovery of novel small molecule orally bioavailable C-X-C chemokine receptor 4 antagonists that are potent inhibitors of T-tropic (X4) HIV-1 replication.
Skerlj RT; Bridger GJ; Kaller A; McEachern EJ; Crawford JB; Zhou Y; Atsma B; Langille J; Nan S; Veale D; Wilson T; Harwig C; Hatse S; Princen K; De Clercq E; Schols D
J Med Chem; 2010 Apr; 53(8):3376-88. PubMed ID: 20297846
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and SAR of novel CXCR4 antagonists that are potent inhibitors of T tropic (X4) HIV-1 replication.
Skerlj R; Bridger G; McEachern E; Harwig C; Smith C; Wilson T; Veale D; Yee H; Crawford J; Skupinska K; Wauthy R; Yang W; Zhu Y; Bogucki D; Di Fluri M; Langille J; Huskens D; De Clercq E; Schols D
Bioorg Med Chem Lett; 2011 Jan; 21(1):262-6. PubMed ID: 21109432
[TBL] [Abstract][Full Text] [Related]
3. Design of novel CXCR4 antagonists that are potent inhibitors of T-tropic (X4) HIV-1 replication.
Skerlj R; Bridger G; McEachern E; Harwig C; Smith C; Kaller A; Veale D; Yee H; Skupinska K; Wauthy R; Wang L; Baird I; Zhu Y; Burrage K; Yang W; Sartori M; Huskens D; De Clercq E; Schols D
Bioorg Med Chem Lett; 2011 Mar; 21(5):1414-8. PubMed ID: 21295470
[TBL] [Abstract][Full Text] [Related]
4. HIV co-receptors as targets for antiviral therapy.
Schols D
Curr Top Med Chem; 2004; 4(9):883-93. PubMed ID: 15134547
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and structure-activity relationships of azamacrocyclic C-X-C chemokine receptor 4 antagonists: analogues containing a single azamacrocyclic ring are potent inhibitors of T-cell tropic (X4) HIV-1 replication.
Bridger GJ; Skerlj RT; Hernandez-Abad PE; Bogucki DE; Wang Z; Zhou Y; Nan S; Boehringer EM; Wilson T; Crawford J; Metz M; Hatse S; Princen K; De Clercq E; Schols D
J Med Chem; 2010 Feb; 53(3):1250-60. PubMed ID: 20043638
[TBL] [Abstract][Full Text] [Related]
6. Highly potent and orally active CCR5 antagonists as anti-HIV-1 agents: synthesis and biological activities of 1-benzazocine derivatives containing a sulfoxide moiety.
Seto M; Aikawa K; Miyamoto N; Aramaki Y; Kanzaki N; Takashima K; Kuze Y; Iizawa Y; Baba M; Shiraishi M
J Med Chem; 2006 Mar; 49(6):2037-48. PubMed ID: 16539392
[TBL] [Abstract][Full Text] [Related]
7. The molecular pharmacology of AMD11070: an orally bioavailable CXCR4 HIV entry inhibitor.
Mosi RM; Anastassova V; Cox J; Darkes MC; Idzan SR; Labrecque J; Lau G; Nelson KL; Patel K; Santucci Z; Wong RS; Skerlj RT; Bridger GJ; Huskens D; Schols D; Fricker SP
Biochem Pharmacol; 2012 Feb; 83(4):472-9. PubMed ID: 22146583
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and structure-activity relationships of phenylenebis(methylene)-linked bis-azamacrocycles that inhibit HIV-1 and HIV-2 replication by antagonism of the chemokine receptor CXCR4.
Bridger GJ; Skerlj RT; Padmanabhan S; Martellucci SA; Henson GW; Struyf S; Witvrouw M; Schols D; De Clercq E
J Med Chem; 1999 Sep; 42(19):3971-81. PubMed ID: 10508445
[TBL] [Abstract][Full Text] [Related]
9. Synthesis, SAR, and biological evaluation of oximino-piperidino-piperidine amides. 1. Orally bioavailable CCR5 receptor antagonists with potent anti-HIV activity.
Palani A; Shapiro S; Josien H; Bara T; Clader JW; Greenlee WJ; Cox K; Strizki JM; Baroudy BM
J Med Chem; 2002 Jul; 45(14):3143-60. PubMed ID: 12086500
[TBL] [Abstract][Full Text] [Related]
10. Anti-human immunodeficiency virus activity of novel aminoglycoside-arginine conjugates at early stages of infection.
Cabrera C; Gutiérrez A; Blanco J; Barretina J; Litovchick A; Lapidot A; Evdokimov AG; Clotet B; Esté JA
AIDS Res Hum Retroviruses; 2000 May; 16(7):627-34. PubMed ID: 10791873
[TBL] [Abstract][Full Text] [Related]
11. The novel CXCR4 antagonist KRH-3955 is an orally bioavailable and extremely potent inhibitor of human immunodeficiency virus type 1 infection: comparative studies with AMD3100.
Murakami T; Kumakura S; Yamazaki T; Tanaka R; Hamatake M; Okuma K; Huang W; Toma J; Komano J; Yanaka M; Tanaka Y; Yamamoto N
Antimicrob Agents Chemother; 2009 Jul; 53(7):2940-8. PubMed ID: 19451305
[TBL] [Abstract][Full Text] [Related]
12. Piperazine-based CCR5 antagonists as HIV-1 inhibitors. II. Discovery of 1-[(2,4-dimethyl-3-pyridinyl)carbonyl]-4- methyl-4-[3(S)-methyl-4-[1(S)-[4-(trifluoromethyl)phenyl]ethyl]-1-piperazinyl]- piperidine N1-oxide (Sch-350634), an orally bioavailable, potent CCR5 antagonist.
Tagat JR; Steensma RW; McCombie SW; Nazareno DV; Lin SI; Neustadt BR; Cox K; Xu S; Wojcik L; Murray MG; Vantuno N; Baroudy BM; Strizki JM
J Med Chem; 2001 Oct; 44(21):3343-6. PubMed ID: 11585438
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of HIV infection by CXCR4 and CCR5 chemokine receptor antagonists.
De Clercq E; Schols D
Antivir Chem Chemother; 2001; 12 Suppl 1():19-31. PubMed ID: 11594685
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of human immunodeficiency virus replication by a dual CCR5/CXCR4 antagonist.
Princen K; Hatse S; Vermeire K; Aquaro S; De Clercq E; Gerlach LO; Rosenkilde M; Schwartz TW; Skerlj R; Bridger G; Schols D
J Virol; 2004 Dec; 78(23):12996-3006. PubMed ID: 15542651
[TBL] [Abstract][Full Text] [Related]
15. The antiviral activity of the CXCR4 antagonist AMD3100 is independent of the cytokine-induced CXCR4/HIV coreceptor expression level.
Princen K; Hatse S; Vermeire K; Bridger GJ; Skerlj RT; De Clercq E; Schols D
AIDS Res Hum Retroviruses; 2003 Dec; 19(12):1135-9. PubMed ID: 14709250
[TBL] [Abstract][Full Text] [Related]
16. Anti-HIV small-molecule binding in the peptide subpocket of the CXCR4:CVX15 crystal structure.
Cox BD; Prosser AR; Katzman BM; Alcaraz AA; Liotta DC; Wilson LJ; Snyder JP
Chembiochem; 2014 Jul; 15(11):1614-20. PubMed ID: 24990206
[TBL] [Abstract][Full Text] [Related]
17. Peptide-lead CXCR4 antagonists with high anti-HIV activity.
Fujii N; Tamamura H
Curr Opin Investig Drugs; 2001 Sep; 2(9):1198-202. PubMed ID: 11717804
[TBL] [Abstract][Full Text] [Related]
18. Highly potent inhibition of human immunodeficiency virus type 1 replication by TAK-220, an orally bioavailable small-molecule CCR5 antagonist.
Takashima K; Miyake H; Kanzaki N; Tagawa Y; Wang X; Sugihara Y; Iizawa Y; Baba M
Antimicrob Agents Chemother; 2005 Aug; 49(8):3474-82. PubMed ID: 16048963
[TBL] [Abstract][Full Text] [Related]
19. Structure-function relationship of novel X4 HIV-1 entry inhibitors - L- and D-arginine peptide-aminoglycoside conjugates.
Hegde R; Borkow G; Berchanski A; Lapidot A
FEBS J; 2007 Dec; 274(24):6523-36. PubMed ID: 18028446
[TBL] [Abstract][Full Text] [Related]
20. Blockade of X4-tropic HIV-1 cellular entry by GSK812397, a potent noncompetitive CXCR4 receptor antagonist.
Jenkinson S; Thomson M; McCoy D; Edelstein M; Danehower S; Lawrence W; Wheelan P; Spaltenstein A; Gudmundsson K
Antimicrob Agents Chemother; 2010 Feb; 54(2):817-24. PubMed ID: 19949058
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]